KDU731 is primarily utilized in the field of parasitology, particularly in the study and treatment of malaria. It acts as a potent inhibitor of the Plasmodium phosphatidylinositol 4-kinase (PI4K), an enzyme critical for the survival and replication of the malaria parasite. By targeting this enzyme, KDU731 effectively disrupts the parasite's life cycle, making it a promising candidate for antimalarial drug development. Its application extends to both research settings, where it is used to understand the molecular mechanisms of Plasmodium, and preclinical studies aimed at evaluating its efficacy and safety as a potential therapeutic agent. Additionally, KDU731 has shown potential in combating drug-resistant strains of malaria, offering a new avenue for addressing the growing challenge of resistance to existing antimalarial treatments.